PEGylated PDZ peptide reduces LPS-induced systemic inflammation, restores tissue integrity, decreases pro-inflammatory cytokines, and modulates macrophage populations, showing potential as a therapeutic for systemic inflammation.

Dermal preadipocytes produce T cell chemokines in response to IFNγ, driving the recruitment and activation of type 1 effector T cells in allergic contact dermatitis.

Type I IFN is a key determinant of pathogenic neutrophil activity and drives tissue pathology through modulation of IL-18 levels during genital HSV infection.

Knockout of Terc impedes effective immune defense against bacterial lung infections in mice, exacerbating disease course and revealing the critical function of Terc in pulmonary immunity.

Expression of an interleukin that is immune suppressive (IL-37) in mice is able to limit inflammation in the brain after acute inflammatory events and prevent loss of cognitive abilities in a mouse model of AD.

Insulin secreting cells harbor distinct subpopulations of insulin granules and loss of one or the other correlates strongly with secretory deficiencies characterizing type-1 or type-2 diabetes.

A short treatment of the NOD mouse model of type-1 diabetes with I-BET151, a small molecule bromodomain blocker, provides long-term protection from disease by inducing macrophages to adapt an anti-inflammatory tenor whilst promoting islet β cell regeneration.

Osteogenic growth peptide displays agonistic activity at CB2.

The treatment of injury from volumetric muscle loss with Maresin 1 reduces inflammation and fibrosis, driving improvements in the recovery of muscle strength.